CCL2 and neoplasm: Palbociclib combined with MEK inhibitors was demonstrated to lead to tumor cell senescence by expressing activated ligands for NK cells, such as the NKG2D ligands and intercellular adhesion molecule 1 (ICAM1), that drive the recruitment of NK cells (CCL2, CCL4, CCL5, CXCL10) and activate NK cells (IL-15, IL-18, TNF-α) in lung cancer models [47].